NMPA-2021-0004-V304

Type IB variation for application NMPA-2021-0004. Type IB variation: Formulation Change for Neprilozone — major revision

Variation Number
NMPA-2021-0004-V304
Type
Type IB
Application
NMPA-2021-0004
Change
CHG-2021-0004
Status
In Progress
Fee
€4,495
Submitted
—
Approved
—
Description

Type IB variation: Formulation Change for Neprilozone — major revision